Investigation of the Safety and Feasibility of AAV1/SERCA2a Gene Transfer in Patients With Chronic Heart Failure and a Left Ventricular Assist Device

Trial Profile

Investigation of the Safety and Feasibility of AAV1/SERCA2a Gene Transfer in Patients With Chronic Heart Failure and a Left Ventricular Assist Device

Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Feb 2016

At a glance

  • Drugs SERCA 2a gene therapy (Primary)
  • Indications Heart failure
  • Focus Adverse reactions; Proof of concept
  • Acronyms SERCA2a-LVAD
  • Most Recent Events

    • 23 Feb 2016 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 09 Sep 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 11 Aug 2014 The first patient has been dosed according to a Celladon media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top